Android app Apple app link

Sana Biotechnology Gets FDA Fast Track Designation for SC291 Cell Therapy

By MarketWatch   |   3 months ago
Sana Biotechnology Gets FDA Fast Track Designation for SC291 Cell Therapy

Sana Biotechnology's proposed treatment for lupus, SC291, has received fast track designation from the FDA. Developed using Sana's hypoimmune platform, the CD19-directed allogeneic CAR T cell therapy is being evaluated in a trial for B-cell mediated autoimmune diseases.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.